F
Francoise Berger
Researcher at Lyon College
Publications - 24
Citations - 1084
Francoise Berger is an academic researcher from Lyon College. The author has contributed to research in topics: Angioimmunoblastic T-cell lymphoma & Gene. The author has an hindex of 7, co-authored 24 publications receiving 1017 citations. Previous affiliations of Francoise Berger include University of Toulouse.
Papers
More filters
Journal ArticleDOI
The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells
Laurence de Leval,David S. Rickman,Caroline Thielen,Aurélien de Reyniès,Yenlin Huang,Yenlin Huang,Georges Delsol,Laurence Lamant,Karen Leroy,Karen Leroy,Josette Brière,Thierry Jo Molina,Francoise Berger,Christian Gisselbrecht,Luc Xerri,Philippe Gaulard,Philippe Gaulard +16 more
TL;DR: It is suggested that the AITL spectrum may be wider than suspected, as a subset of CD30(-) PTCLs-u may derive from or be related to AIT l, and T(FH) cells represent the normal counterpart of AITl.
Journal ArticleDOI
Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients
Y. Bastion,Catherine Sebban,Francoise Berger,Pascale Felman,Gilles Salles,Charles Dumontet,P. A. Bryon,B. Coiffier +7 more
TL;DR: Transformation is an early event in the course of the disease and is mainly observed in patients with known adverse prognostic factors or those who do not achieve CR after initial treatment, and may be useful to select follicular lymphoma patients for intensive therapeutic approaches.
Journal ArticleDOI
Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study
Jean-Marie Michot,Danielle Canioni,Henda Driss,Laurent Alric,Patrice Cacoub,Felipe Suarez,Felipe Suarez,David Sibon,David Sibon,Catherine Thieblemont,Jehan Dupuis,Benjamin Terrier,Cyrille Feray,Hervé Tilly,Stanislas Pol,Véronique Leblond,Catherine Settegrana,Pascaline Rabiega,Yoann Barthe,Houria Hendel-Chavez,Florence Nguyen-Khac,Hélène Merle-Béral,Francoise Berger,Thierry Jo Molina,Frédéric Charlotte,Fabrice Carrat,Frederic Davi,Olivier Hermine,Olivier Hermine,Caroline Besson +29 more
TL;DR: The data support that AT improves the outcomes of HCV‐associated NHLs and the impact of new AT regimen with protease inhibitor needs to be investigated in this setting.
Journal ArticleDOI
Young Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B
Thierry Jo Molina,Danielle Canioni,Christiane Copie-Bergman,Christian Recher,Josette Brière,Corinne Haioun,Francoise Berger,Christophe Fermé,Marie-Christine Copin,Olivier Casasnovas,Catherine Thieblemont,Tony Petrella,Karen Leroy,Gilles Salles,Bettina Fabiani,Franck Morschauser,Nicolas Mounier,Bertrand Coiffier,Fabrice Jardin,Philippe Gaulard,Jean-Philippe Jais,Hervé Tilly +21 more
TL;DR: In this article, the authors determined whether any tumor biomarkers could account for the survival advantage observed in the LNH 03-2B trial among patients with diffuse large B-cell lymphoma (DLBCL) and low-intermediate risk according to the International Prognostic Index when treated with dose-intensive rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP).
Journal ArticleDOI
R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network
Christiane Pott,Eva Hoster,Kheira Beldjord,Elizabeth Macintyre,Sebastian Böttcher,Vahid Asnafi,Reiner Siebert,Anne Plonquet,Evelyne Callet-Bauchut,Vincent Ribrag,Wolfram Klapper,Francoise Berger,Michael Unterhalt,Michael Kneba,Wolfgang Hiddemann,Martin Dreyling,Olivier Hermine,Marie-Helene Delfau +17 more
TL;DR: High-dose consolidation followed by ASCT demonstrated a high impact on tumor reduction in the pooled treatment arms and increased the BM MR rate from 50% to 75% (p = 0.0001, paired samples).